Evidence map›Paper›PMID 23244299›Full record

ArticleMolecular pharmaceutics2013

Nanoassembly of surfactants with interfacial drug-interactive motifs as tailor-designed drug carriers.

Xiang Gao, Yixian Huang, Alexander M Makhov, Michael Epperly, Jianqin Lu, Sheila Grab, Peijun Zhang, Lisa Rohan, Xiang-Qun Xie, Peter Wipf and 2 more

Abstract read
In one paragraph

Article in Molecular pharmaceutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. RSC advances · 2019
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. An improved D-α-tocopherol-based nanocarrier for targeted delivery of doxorubicin with reversal of multidrug resistance.Journal of controlled release : official journal of the Controlled Release Society · 2014
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xiang GaoDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, United States.
Yixian Huang
Alexander M Makhov
Michael Epperly
Jianqin Lu
Sheila Grab
Peijun Zhang
Lisa Rohan
Xiang-Qun Xie
Peter Wipf
Joel Greenberger
Song Li

Funding

Training and EducationU19AI068021 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BAYIR, HÜLYA · 2005 to 2019
$44.4M
University of Pittsburgh Center for Chemical DiversityP50GM067082 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WIPF, PETER · 2002 to 2012
$18.6M
Non Viral Gene Therapy for Lung InjuryR01HL091828 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LI, SONG · 2009 to 2012
$1.5M
Structure and function of membrane receptor signaling complex in bacterial chemotR01GM085043 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ZHANG, PEIJUN · 2009 to 2013
$1.4M
Rational Design of Lipidic Vectors for Mitochondria-Targeted AntioxidantsR01GM102989 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LI, SONG · 2013 to 2016
$1.1M
NHLBI NIH HHS R01 HL091828NIAID NIH HHS U19 AI068021NIAID NIH HHS U19 AI068021-06NIGMS NIH HHS P50 GM067082NIGMS NIH HHS P50GM067082NIGMS NIH HHS R01 GM085043NIGMS NIH HHS R01 GM102989PHS HHS HHS0100200800062CPHS HHS NIH/NHLBI R01 HL091828PHS HHS NIH/NIGMS R01GM085043
6 · The paper itself

Abstract

PEGylated lipopeptide surfactants carrying drug-interactive motifs specific for a peptide-nitroxide antioxidant, JP4-039, were designed and constructed to facilitate the solubilization of this drug candidate as micelles and emulsion nanoparticles. A simple screening process based on the ability that prevents the formation of crystals of JP4-039 in aqueous solution was used to identify agents that have potential drug-interactive activities. Several protected lysine derivatives possessing this activity were identified, of which α-Fmoc-ε-t-Boc lysine is the most potent, followed by α-Cbz- and α-iso-butyloxycarbonyl-ε-t-Boc-lysine. Using a polymer-supported liquid-phase synthesis approach, a series of synthetic lipopeptide surfactants with PEG headgroup, varied numbers and geometries of α-Fmoc or α-Cbz-lysyl groups located at interfacial region as the drug-interactive domains, and oleoyl chains as the hydrophobic tails were synthesized. All α-Fmoc-lysyl-containing lipopeptide surfactants were able to solubilize JP4-039 as micelles, with enhanced solubilizing activity for surfactants with increased numbers of α-Fmoc groups. The PEGylated lipopeptide surfactants with α-Fmoc-lysyl groups alone tend to form filamentous or wormlike micelles. The presence of JP4-039 transformed α-Fmoc-containing filamentous micelles into dots and barlike mixed micelles with substantially reduced sizes. Fluorescence quenching and NMR studies revealed that the drug and surfactant molecules were in close proximity in the complex. JP4-039-loaded emulsion carrying α-Cbz-containing surfactants demonstrated enhanced stability over drug-loaded emulsion without lipopeptide surfactants. JP4-039 emulsion showed a significant mitigation effect on mice exposed to a lethal dose of radiation. PEGylated lipopeptides with an interfacially located drug-interactive domain are therefore tailor-designed formulation materials potentially useful for drug development.

Indexed as

AnimalsAntioxidantsChemistry, PharmaceuticalDrug CarriersDrug DesignDrug InteractionsEmulsionsLipopeptidesLysineMagnetic Resonance SpectroscopyMiceMicellesModels, MolecularNanoparticlesNitrogen OxidesPeptidesAntioxidantsDrug CarriersEmulsionsepsilon-tert-butyloxycarbonyl-lysineJP4-039LipopeptidesLysineMicellesNitrogen OxidesPeptidesPolymersSurface-Active Agents

Identifiers

PMID23244299
PMCPMC3540186

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.